en Pharmacokinetics/Dynamics Pharmacokinetics/Dynamics Clinical research article Clinical research article <p><span style="font-size:12px;"><span style="font-family:Arial;"><span style="line-height:150%"><span sans-serif=""><b><span new="" roman="" times="">Background: </span></b><span new="" roman="" times="">Mucositis is acute oral toxicity induced by radiation or systemic cytotoxic chemotherapy agents in patients with cancer that may lead to discontinuing the treatment or reducing the administered dose. In this study, we aimed to evaluate the preventive effect of oral L-carnitine on chemotherapy-induced mucositis.<br /> <b>Methods: </b>This prospective clinical trial employed a double-blind, randomized, placebo-controlled design. All consecutive cancer patients who met the inclusion criteria were enrolled in the oncology ward of Imam Khomeini Hospital, Urmia, Iran. Patients were randomly allocated to one of two groups: one receiving L-Carnitine 1000 mg three times daily (total dose 3000 mg/day) and the other receiving a placebo. Mucositis severity was evaluated clinically using the WHO scoring system every week throughout the 21-day study period.<br /> <b>Results: </b>L-carnitine supplementation did not significantly reduce the incidence of mucositis compared to placebo (p-value = 0.748). Among the 40 enrolled patients, exactly half (50%) developed mucositis. As per the WHO grading system, the distribution of mucositis severity was as follows: 15% for grade 1, 30% for grade 2, and 5% for grade 3. Notably, no patients experienced grade 4 mucositis, the most severe category. Grade 2 mucositis represented the most common presentation, affecting 29.2% of the placebo group and 31.3% of the L-Carnitine group.<br /> <b>Conclusion: </b>Our investigation did not identify a statistically significant impact of L-Carnitine supplementation on the incidence, severity progression, or WHO grade distribution of chemotherapy-induced oral mucositis compared to the placebo group.</span><span style="line-height:150%"><span style="font-family:"Times New Roman","serif""></span></span></span></span><br /> &nbsp;</span></span></p> ,L-Carnitine,mucositis,chemotherapy,cancer,antineoplastic drugs 0 0 http://ppj.phypha.ir/browse.php?a_code=A-10-2525-1&slc_lang=en&sid=1 Afshin Shiva afshin.shiva@gmail.com 3200319475328460039039 3200319475328460039039 No Department of Clinical Pharmacy, School of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran Mahroo Ghasempour gmr.mahroo@yahoo.com 3200319475328460039040 3200319475328460039040 No School of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada Rahim Asghari Rahimasghari@gmail.com 3200319475328460039041 3200319475328460039041 No Department of Internal Medicine, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran Shima Hatamkhani hatamkhani.sh@umsu.ac.ir 3200319475328460039042 0000000241668977 Yes Department of Clinical Pharmacy, School of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran